Codexis Bio (CDXS): רווח למניה בשנים עשר החודשים האחרונים

Codexis, Inc. (CDXS) is recognized as the gold standard in biocatalysis, having earned the full trust of the largest pharmaceutical behemoths. The profit per unit trend over the last 12 months reflects market dynamics where -0.34 determines the current value of the metric. Growth is driven by the CodeEvolver platform for creating unique proteins, while cost optimization is achieved through the use of certified contract manufacturing while maintaining the R&D center in California.

The development of biocatalysts within a secure US perimeter provides Codexis, Inc. (CDXS) with stability, as reflected in the trailing twelve-month (TTM) net income per share. This indicator is calculated by dividing the total annual profit by the number of shares, allowing investors to assess the real efficiency of the business regardless of issuance factors and determine the fair market value of the security.